Plain Language Summary {#S0001}
======================

Dysmenorrhea can negatively affect women's quality of life and productivity, and ethinylestradiol (EE)/drospirenone (DRSP) may be used to ease the burden of dysmenorrhea. A recent Phase III study of EE/DRSP demonstrated that when compared with a 28-day cyclic regimen, a flexible extended regimen was more effective at alleviating menstrual pain.

Heatmaps are visual tools that help represent many data points and identify patterns in data. In this analysis, clinical data from the previously published phase III study of EE/DRSP were re-evaluated to create heatmaps and assess differences in menstrual pain patterns and intensities between the two treatment groups. As a result, differences in menstrual pain pattern changes were observed between the groups. Regular peaks of menstrual pain were alleviated in the patients treated with the extended regimen but not in those with the cyclic regimen.Patients with lower baseline dysmenorrhea scores were more likely than those with higher baseline scores to have fewer days with menstrual pain and a greater reduction in the severity of menstrual pain.Patients with primary dysmenorrhea were more likely to experience lower intensities of menstrual pain than those with secondary dysmenorrhea after the treatment.Among the patients with secondary dysmenorrhea, those who had lower baseline dysmenorrhea scores and received the extended regimen experienced a greater reduction in the number of days with menstrual pain compared to those who received the cyclic regimen.

Introduction {#S0002}
============

Dysmenorrhea refers to pathological symptoms associated with menstruation.[@CIT0001] Primary dysmenorrhea refers to dysmenorrhea that cannot be attributed to a specific cause, and secondary dysmenorrhea is associated with a preexisting gynecological disorder such as endometriosis. Patients present with menstrual pain symptoms such as focal pain (eg, lower abdominal pain, low back pain, and pain radiating to the legs) with the onset of menses.[@CIT0002] Some patients also experience nausea, headache, dizziness, insomnia, anxiety/irritability, diarrhea, and depression.[@CIT0002]

Dysmenorrhea not only affects women's health due to pain during menstruation, but has also been shown to have a negative impact on their quality of life (QOL).[@CIT0003],[@CIT0004] According to a comprehensive review including large community-based samples of women, dysmenorrhea affects 16% to 91% of women during menstruation, while two to 29% of cases are classified as severe.[@CIT0005] A strong association has been reported between severity of dysmenorrhea and poor school attendance and performance.[@CIT0006],[@CIT0007]

Dysmenorrhea also poses a considerable economic burden, given its impact on work productivity and healthcare resource utilization. A survey conducted in over 20,000 women in Japan revealed that 17.2% of the women experienced work productivity loss due to menstrual symptoms within the past three months.[@CIT0008] In the survey, an annual economic burden of menstrual symptoms in the Japanese female population was estimated to be 683 billion Japanese yen.[@CIT0008] A previous retrospective study of Japanese claims data found that direct costs in the year after diagnosis for women with dysmenorrhea were two to three times higher than those for women without dysmenorrhea.[@CIT0009]

According to the guidelines of the Japan Society of Obstetrics and Gynecology, treatment of dysmenorrhea should consist of analgesics, such as non-steroidal anti--inflammatory drugs, and hormonal contraceptives (such as low-dose estrogen/progestin or levonorgestrel-releasing intrauterine systems).[@CIT0010] A study in women with dysmenorrhea suggested that a flexible extended regimen of ethinylestradiol (EE)/drospirenone (DRSP) administered for up to 120 days significantly reduced the number of days with menstrual pain compared with a standard 28-day cyclic regimen (a mean of 3.4 fewer days with dysmenorrheic pain).[@CIT0011] However, limitations of that study included that the results did not indicate individual patients' menstrual pain patterns and daily pain levels, but rather combined all patient data.[@CIT0011]

Usual methods for measuring quantitative data are not necessarily suited to representing qualitative data, such as pain. A heatmap is one visualization method that shows the magnitude of values using shades of color and may provide an effective method for measuring individual pain data. By arranging the colors such that they do not overlap, it is possible to maintain visibility and read all samples widely and objectively. In healthcare settings, heatmaps are used to provide clear visual illustrations of utilization rates of certain tests among different healthcare providers,[@CIT0012] and to identify differences in the density of important health and social indicators among neighborhoods to inform healthcare decision-making.[@CIT0013] They are also used to visualize high-density data, for example, to detect patterns from chemistry data involving many thousands of different data measurements,[@CIT0014] or to map genetic determinants.[@CIT0015] Because heatmaps represent an effective method of visualizing patterns, heatmapping was used in this analysis to investigate differences in menstrual pain patterns and degrees of pain between the two EE/DRSP treatment groups (flexible extended and 28-day cyclic regimens), based on re-evaluated data from the previously published phase III study of EE/DRSP in Japanese patients with dysmenorrhea,[@CIT0011] and to evaluate the effect of EE/DRSP using a heatmap visualizing daily menstrual pain.

Materials and Methods {#S0003}
=====================

Study Design {#S0003-S2001}
------------

This was a phase III, multicenter, randomized, open-label, active-control, parallel-group study (BAY 86-5300/16114) sponsored by Bayer Yakuhin, Ltd. (Osaka, Japan), and conducted at eight facilities in Japan.[@CIT0011] The study consisted of a 24-week treatment phase followed by a 28-week long-term safety study. Patients considered eligible for inclusion were aged ≥20 years and had primary or secondary dysmenorrhea as shown by a baseline dysmenorrhea score of ≥3 (the sum of two sub-scores describing severity of dysmenorrhea and use of analgesics \[[Table 1](#T0001){ref-type="table"}\]; maximum score is 6) in each of the two menstrual cycles during the baseline observation period. The severity of dysmenorrhea sub-score ranged from 0 (none) to 3 (severe: necessary to stay in bed all day; unable to do any work, including schoolwork or housework), and the use of analgesics score ranged from 0 (none) to 3 (severe: used analgesics for three or more days during the previous \[or current\] menstrual period).Table 1Baseline Dysmenorrhea Score (Sum of Two Sub-Scores)Sub-ScoreSeverityDefinitionScoreSeverity of dysmenorrhea sub-scoreNoneNo impairment of work, including schoolwork and housework0MildSlight impairment of work, including schoolwork and housework1ModerateDesire to lie down to rest. Discomfort interferes with work, including schoolwork and housework2SevereNecessary to stay in bed all day. Discomfort causes inability to work, including schoolwork and housework3Use of analgesics sub-scoreNoneNo pain0MildUse of analgesics for 1 day during the previous(or current) menstrual period1ModerateUse of analgesics for 2 days2SevereUse of analgesics for 3 or more days3

Patients were randomized 1:1 to either the flexible extended regimen group or the 28-day cyclic regimen group. After confirming two menstrual cycles (Visits 2 and 3) during the baseline observation period (from Visit 1 to the start of study drug administration), the study drug was provided at Visit 4 and administration was started from the next menstruation. During the treatment period (from the start of study drug administration to Visit 10), administration of the drug by the flexible extended regimen or 28-day cyclic regimen was continued for 24 weeks until Visit 10. Patients randomized to the flexible extended regimen received one tablet of oral EE 20 μg/DRSP 3 mg every day for at least 24 days and up to 120 days, followed by a four-day interval without study drug administration (cycle of 28 up to 124 days). In the event of three consecutive days of spotting and/or bleeding during days 25−120 of the intake cycle, a four-day interval was given, followed by the start of the next intake cycle. Patients randomized to the 28-day cyclic regimen received one tablet of EE 20 μg/DRSP 3 mg at the same time every day for 24 days, followed by four days of placebo tablet administration. Patients in this group received six cycles of treatment during the treatment phase.

The phase III study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice and met all local legal and regulatory requirements. The protocol and all protocol amendments were reviewed and approved by each study site's Independent Ethics Committee/Institutional Review Board. All patients provided written informed consent before entering the study. The study was registered at ClinicalTrials.gov (NCT01892904).

Pain Measurement {#S0003-S2002}
----------------

The pain measurement methodology, which is a combined assessment of the degree of menstrual pain and the level of interference to daily activities was previously published (hereinafter "menstrual pain score").[@CIT0011] In brief, from Day 25 of treatment, the patients measured the degree of menstrual pain ([Table 2](#T0002){ref-type="table"}) on a daily basis and recorded their scores in eDiary, an electronic platform that allows patients to report outcomes, regardless of the state of menstrual bleeding (withdrawal bleeding). They rated the menstrual pain as mild (no need for analgesics and no impairment of daily activities), moderate (requiring analgesics, but pain was effectively relieved during most cycles; discomfort interferes with usual daily activities), or severe (required analgesics, but achieved no consistent relief from analgesia; discomfort causes inability to work or perform usual activities).Table 2Evaluation Criteria for Menstrual Pain and the Coloration Used for the HeatmapSeverityDefinitionColoration Used for HeatmapNoneNo pain.WhiteMildNo need for analgesics and no impairment of daily activities.Light orangeModerateModerate menstrual pain requiring analgesics. The pain is relieved by taking analgesics. Discomfort interferes with usual daily activities.OrangeSevereAdvanced menstrual pain requiring analgesics. The pain may not be relieved by taking analgesics. Discomfort causes inability to work or perform usual activities.Dark orange

Present Analysis and Heatmapping Methodology {#S0003-S2003}
--------------------------------------------

All the eligible patients who received at least one dose of the study drug were included in this heatmapping analysis. The time period applied in the analysis was from 70 days prior to the start of study drug administration to Day 168, the end of study drug administration. In addition, a quantitative assessment of the intensity of menstrual pain was conducted for a 140-day period from Day 25.

To visualize menstrual pain patterns and intensities among the two treatment groups, the severity of menstrual pain was displayed in color ([Table 2](#T0002){ref-type="table"}), with the patients on the vertical axis and time on the horizontal axis. Patients with dysmenorrhea scores 3--4 and 5--6 at baseline were placed as subgroups on the top and bottom of the map, respectively, and the patients in each subgroup were ordered by the number of days they had menstrual pain prior to the start of study drug administration. Heatmaps for each subgroup of primary and secondary dysmenorrhea were also created, and the patients in each subgroup, dysmenorrhea scores 3--4 and 5--6 at baseline, were ordered by the number of days they had menstrual pain in the heatmap. There were some missing data because data collection relied on patient self-reporting (3.3% and 3.0% in the flexible extended regimen group and 28-day cyclic regimen group, respectively). The missing values were displayed in light gray color, and patients with substantial missing values were arranged above or below the graph.

The numbers of patients who experienced severe pain at least once in the period between Days 25 and 165 were tabulated by treatment group and by subgroups defined by the baseline dysmenorrhea score and were evaluated. Considering that menstrual pains were recurrent events in the same patient over time, the incidence rate was calculated as the number of events across the patients divided by the total number of days assessed. In addition, the marginal mean and rate model was used to estimate the mean cumulative function (MCF) and the rate ratio (RR) with the 95% confidence interval constructed from the robust sandwich estimate of the covariance matrix.[@CIT0016] The same analysis was performed by the subgroups defined by the baseline dysmenorrhea score (3--4 or 5--6). All the analyses were conducted by SAS ver 9.2. Due to the exploratory nature of the analysis conducted after the completion of the study, all analyses were descriptive.

Results {#S0004}
=======

Patients {#S0004-S2001}
--------

In the phase III study of EE/DRSP,[@CIT0011] 212 patients received the study medication. Therefore, the full analysis set consisted of 212 patients, 105 randomized to the flexible extended regimen group and 107 to the 28-day cycle regimen group. Patient baseline characteristics were previously described.[@CIT0011] In brief, all patients were Asian, and had a mean ± standard deviation (SD) age of 29.7±6.4 years, mean body mass index 20.6±2.5 kg/m^2^, and mean menstrual cycle length SD 29.2±4.5 days. The proportion of the patients with primary dysmenorrhea was 71.4% and 68.2% in the flexible extended regimen group and cyclic regimen group, respectively. Of the 64 patients with secondary dysmenorrhea, 42 patients had endometriosis, 20 had uterine fibrosis, and 11 had adenomyosis. The proportion of the patients with baseline dysmenorrhea scores of 3--4 was 36.2% and 43.0% in the flexible extended regimen group and the cyclic regimen group, respectively, while that with baseline dysmenorrhea scores of 5--6 was 63.8% and 57.0% in the flexible extended regimen group and the cyclic regimen group, respectively.

Heatmap Visualization Using the Full Analysis Set {#S0004-S2002}
-------------------------------------------------

There was a difference in the menstrual pain patterns after administration of the study drug between the flexible extended regimen group ([Figure 1A](#F0001){ref-type="fig"}) and the 28-day cyclic regimen group ([Figure 1B](#F0001){ref-type="fig"}) as visualized on the heatmap. In both groups, two or more peaks of pain thought to be due to menstruation were observed before the start of study drug administration. After the start of administration, the two treatment groups presented different peak patterns of menstrual pain. While the degree of menstrual pain appeared to be alleviated in both groups initially, regular peak patterns of menstrual pain were still observed in the 28-day cyclic regimen group but not in the flexible extended regimen group. The map suggested that severe menstrual pain in the flexible extended regimen group was more likely to be alleviated after study drug administration, compared with the cyclic regimen group. Over the 140 days of the evaluation period, patients treated with the flexible extended regimen reported on average 3.4 fewer days with menstrual pain than those with the 28-day cyclic regimen (95% CI −6.5 to −0.3; P=0.03). Patients with low baseline dysmenorrhea scores (3--4), especially those in the flexible extended regimen group, tended to have a lower degree of menstrual pain at the peak of pain after study drug administration compared with those in the 28-day cyclic regimen group. Although patients with high baseline dysmenorrhea scores (5--6) experienced lower intensities of menstrual pain after administration, when compared with patients with low baseline scores, they tended to continue to experience menstrual pain after administration, and the peak post-administration pain levels were relatively higher in the cyclic regimen group compared to the flexible extended regimen group.Figure 1Overall menstrual pain scores over 24 weeks in the full analysis set following treatment with the flexible extended regimen (**A**) and the 28-day cyclic regimen (**B**), as shown with heatmapping. The reference line at Day 0 indicates the first day of study drug administration. Lower baseline dysmenorrhea scores (3--4) are shown in the top half of the heatmap, and higher baseline dysmenorrhea scores (5--6) in the bottom half.

Exploratory Analysis {#S0004-S2003}
--------------------

The percentage of the patients who experienced severe menstrual pain more than once was 15.2% (16/105) in the flexible extended regimen group and 27.1% (29/107) in the 28-day cyclic regimen group ([Table 3](#T0003){ref-type="table"}). Similarly, in the analysis by baseline score, the proportion of the patients who experienced severe menstrual pain tended to be lower in the flexible extended regimen group than in the cyclic regimen group ([Table 3](#T0003){ref-type="table"}).Table 3Number of Patients with Menstrual Pain by IntensityDysmenorrhea Score at BaselineFlexible Extended Regimen28-Day Cyclic RegimenTotaln105100.0%107100.0%None010.9%Mild3129.5%2018.7%Moderate5855.2%5753.3%Severe1615.2%2927.1%3--4n38100.0%46100.0%None012.2%Mild1642.1%1532.6%Moderate1847.4%2452.2%Severe410.5%613.0%5--6n67100.0%61100.0%None00Mild1522.4%58.2%Moderate4059.7%3354.1%Severe1217.9%2337.7%

The percentage of the days with severe menstrual pain in the total number of the days assessed was 0.23% (32/13,884) in the flexible extended regimen group and 0.58% (78/13,377) in the 28-day cyclic regimen group ([Table 4](#T0004){ref-type="table"}), and the MCF for severe menstrual pain for both groups was plotted ([Figure 2](#F0002){ref-type="fig"}); the rate ratio (RR) for severe menstrual pain in the 28-day cyclic regimen group vs the flexible extended regimen group was 2.478 (95% CI: 1.2, 5.2) ([Table 4](#T0004){ref-type="table"}). The analysis for severe menstrual pain was also performed by baseline dysmenorrhea score; the results of the heatmapping and the RR for the 28-day cyclic regimen group vs the flexible extended regimen are shown in [Table 4](#T0004){ref-type="table"}.Table 4Rate Ratios for Severe Menstrual Pain for the 28-Day Cyclic Regimen vs Flexible Extended Regimen According to Baseline Dysmenorrhea ScoreDysmenorrhea Score at BaselineTreatment GroupTotal Number of Days AssessedTotal Number of Days with Severe Pain Score (%)RR:28-Day Cyclic Regimen Group/Flexible Extended Regimen (95% CI)TotalFlexible extended regimen group13,88432 (0.23)2.478 (1.182--5.196)28-day cyclic regimen group13,37778 (0.58)3--4Flexible extended regimen group50375 (0.10)1.624 (0.456--5.778)28-day cyclic regimen group55319 (0.16)5--6Flexible extended regimen group884727 (0.31)2.832 (1.251--6.408)28-day cyclic regimen group784669 (0.88)[^1] Figure 2Mean cumulative function of the flexible extended regimen and the 28-day cyclic regimen.

Heatmap Visualization by Dysmenorrhea Type {#S0004-S2004}
------------------------------------------

The pain scores after treatment with the flexible extended regimen and the 28-day cyclic regimen according to dysmenorrhea subgroup type using heatmapping are shown in [Figure 3](#F0003){ref-type="fig"} (primary dysmenorrhea) and [Figure 4](#F0004){ref-type="fig"} (secondary dysmenorrhea).Figure 3Menstrual pain scores as shown by heatmapping after treatment with the flexible extended regimen (**A**) or the 28-day cyclic regimen (**B**) in the group with primary dysmenorrhea. Lower baseline dysmenorrhea scores (3--4) are shown in the top half of the heatmap, and higher baseline dysmenorrhea scores (5--6) in the bottom half.Figure 4Menstrual pain scores as shown by heatmapping after treatment with the flexible extended regimen (**A**) or the 28-day cyclic regimen (**B**) in the group with secondary dysmenorrhea. Lower baseline dysmenorrhea scores (3--4) are shown in the top half of the heatmap, and higher baseline dysmenorrhea scores (5--6) in the bottom half.

When assessed separately by primary and secondary dysmenorrhea, patients with low baseline dysmenorrhea scores in both subgroups were likely to gain some pain relief. Although the secondary dysmenorrhea patients, compared with the primary dysmenorrhea patients, tended to be less likely to experience pain relief, the secondary dysmenorrhea patients treated with the flexible extended regimen, compared with those with the 28-day cyclic regimen, experienced a greater reduction in the number of days with menstrual pain (mean±SD: 13.8±10.7 versus 17.8±13.4 days), particularly those with low baseline dysmenorrhea scores.

Discussion {#S0005}
==========

Dysmenorrhea is considered to affect almost all menstruating women at some point in their lives, with almost one-third reporting severe menstrual pain.[@CIT0005] Therapeutic improvements are needed to reduce the incidence and severity of dysmenorrhea, its impact on individual women's QOL[@CIT0003],[@CIT0004] and its wider socioeconomic impact.[@CIT0007],[@CIT0008]

In the previously published phase III study of EE/DRSP, the number of days with menstrual pain was 3.4 days fewer in the flexible extended EE/DRSP regimen group compared with the standard cyclic 28-day EE/DRSP regimen group.[@CIT0011] In this analysis, data from the phase III study were used to generate heatmaps to present comparative menstrual pain patterns among women with dysmenorrhea treated with the two EE/DRSP regimens and qualitatively visualize changes in menstrual pain levels during treatment. The heatmapping analysis of the daily menstrual pain data enabled us to visualize the degree of menstrual pain and the time-dependent change before and after administration of the study drug.

The heatmap data demonstrated that overall, EE/DRSP reduced the degree of menstrual pain in both regimen groups. The heatmap suggested visually that patients with low baseline dysmenorrhea scores (3--4) were more likely to experience lower intensities of menstrual pain through administration of EE/DRSP, while in patients with high baseline dysmenorrhea scores (5--6), their menstrual pain was not completely alleviated, but some relief could be expected in both groups. The same results were obtained using the RR.

When assessed separately by dysmenorrhea type, patients with low baseline dysmenorrhea scores in both subgroups were also more likely to achieve pain relief to lower intensities. The heatmap suggested that although the secondary dysmenorrhea patients overall, compared with the primary dysmenorrhea patients, tended to be less likely to experience pain relief, those treated with the flexible extended regimen, compared with those with the 28-day cyclic regimen, experienced a greater reduction in the number of days with menstrual pain.

In recent years, due to the explosion of time-series data generated from the Internet of Things (eg, mobile, sensor, and wearable devices), there has been mounting interest in techniques that have the potential to detect and visualize patterns in non-numerical (sensory or subjective) information. Heatmaps are already used for geographical information systems visualizations.[@CIT0017] The use of heatmapping is now expanding also within the healthcare field, and the most common uses are to gain information on epidemiological or healthcare utilization patterns and inform public health decisions,[@CIT0012],[@CIT0013] or to visualize large datasets.[@CIT0014],[@CIT0015] In cancer research, heatmaps are used to identify mitochondrial RNA switching to discover novel tumor biomarkers[@CIT0018] and to predict patient survival.[@CIT0019] However, heatmapping is not frequently used in the context of clinical studies or to visualize pain scores. Aside from pain scores, heatmapping could potentially be used to visualize subject data related to other areas of women's health, such as volume of menstrual bleeding, and in other areas of study, such as sleep quality. Heatmapping enabled us to obtain new insight that was not apparent in the previous report of the phase III study of EE/DRSP. However, there are limitations to this analysis. The number of patients in the secondary dysmenorrhea subgroup was small, being less than one-third of the total. Therefore, when the patients were further divided into subgroups by baseline dysmenorrhea score, the number of each subgroup became even smaller. Missing values in this analysis were placed on the heatmap in a different color from the overall color scheme, and patients with the missing values were placed above and below the map to maintain the pattern visibility.

Conclusions {#S0006}
===========

The analysis using heatmaps suggested that the flexible extended EE/DRSP treatment regimen was more likely to alleviate the regular occurrence of menstrual pain peaks compared with the 28-day cyclic regimen. The flexible extended regimen appeared to reduce the number of days with menstrual pain and pain levels in the patients with both primary and secondary dysmenorrhea, although the number of the patients in the secondary dysmenorrhea subgroup was small. Heatmapping effectively visualized the daily burden of menstrual pain in the Japanese patients with dysmenorrhea, and may be useful for visualizing individual patient data, including pain scores, in clinical studies, and visually comparing data among different regimens or subgroups.
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